Volume 13, Issue 3 (May-Jun 2019)                   mljgoums 2019, 13(3): 25-30 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Musavi H, Fattah A, Abbasi M. Differential Expression of the KLK2 and KLK3 Genes in Peripheral Blood and Tissues Samples of Iranian Patients with Prostate Cancer. mljgoums. 2019; 13 (3) :25-30
URL: http://mlj.goums.ac.ir/article-1-1207-en.html
1- Student Research Committee, Babol University of Medical Sciences, Babol, Iran, Department of Biochemistry, Faculty of Basic Science, Razi University Kermanshah, Iran
2- Research Center for Health Sciences and Technologies, Semnan University of Medical Sciences, Semnan, Iran
3- Veterinary Medicine, Faculty of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran , Dr_Abbasi_m@yahoo.com
Abstract:   (3584 Views)
              Background and Objectives: Prostate cancer is a highly prevalent malignancy with a high mortality rate in men. Many studies have investigated the diagnostic value of various genes involved in prostate cancer, but there is no data for Kallikrein 2 (KLK2) and Kallikrein 3 (KLK3) expression patterns among Iranian patients. Therefore, we aimed to evaluate the expression of these two genes in Iranian patients with prostate cancer.
              Methods: In this case-control study, three groups consisting of healthy individuals, patients with benign prostatic hyperplasia (BPH) and patients with prostate cancer were studied. Peripheral blood samples were collected from all subjects, mRNA was extracted after cell lysis, and cDNA was synthesized. Real-time PCR was performed to assess gene expression levels relative to a reference gene (18s rRNA gene).
              Results: The KLK2 gene was overexpressed in patients with prostate cancer. KLK2 expression differed significantly between the cancer patients and controls. Relative expression of the KLK3 gene in the BPH group was higher than that in the control and cancer groups. However, we observed no significant difference in the expression of KLK3 between the control and cancer subjects.
              Conclusion: We demonstrate that analysis of KLK2 expression is a favorable method of diagnosing prostate cancer and discriminating normal individuals from those with BPH or prostate cancer. We also found that the KLK3 gene is highly overexpressed in individuals with BPH, which might indicate that this gene is not cancer-specific.
              Keywords: Prostatic Neoplasm, Prostatic Hyperplasia, Kallikreins, Gene Expression.
Full-Text [PDF 839 kb]   (496 Downloads)    
Research Article: Original Paper | Subject: Sport Physiology
Received: 2019/04/15 | Accepted: 2019/04/15 | Published: 2019/04/15 | ePublished: 2019/04/15

1. Geinitz H, Roach III M, Van As N. Radiotherapy in Prostate Cancer: Innovative Techniques and Current Controversies. Berlin: Springer. 2014; 65. [DOI:10.1007/978-3-642-37099-1]
2. Coleman MP, Quaresma M, Berrino F, Lutz J-M, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The lancet oncology. 2008; 9(8): 730-56. doi: 10.1016/S1470-2045(08)70179-7. [DOI:10.1016/S1470-2045(08)70179-7]
3. American Cancer Society.: Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society, 2013. Available online Exit Disclaimer. Last accessed May 2, 2013.
4. American Cancer Society, Prostate Cancer 2010. Available from: http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/index http://www.cancer.org/acs/groups/cid/documents/webcontent/003134-pdf.pdf.
5. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Annals of Oncology. 2009;20(3):556-63. [DOI:10.1093/annonc/mdn642]
6. Arab Yarmohamadi A. Radical retropubic prostatectomy and report of our first experiences in 11 cases. The Iranian Journal of Urology. 1999;22(6):21-4.
7. Mohagheghi M-A, Mosavi-Jarrahi A, Malekzadeh R, Parkin M. Cancer Incidence in Tehran Metropolis: The First Report from the Tehran Population-Based Cancer Registry, 1998 - 2001. Archives of Iranian medicine. 2009;12(1):15-23.
8. Riegman P, Vlietstra R, Van der Korput J, Romijn J, Trapman J. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochemical and biophysical research communications. 1989;159(1):95-102. [DOI:10.1016/0006-291X(89)92409-1]
9. Liu XF, Essand M, Vasmatzis G, Lee B, Pastan I. Identification of three new alternate human kallikrein 2 transcripts: evidence of long transcript and alternative splicing. Biochemical and biophysical research communications. 1999; 264(3): 833-9. [DOI:10.1006/bbrc.1999.1595]
10. Lundwall Å, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS letters. 1987; 214(2): 317-22. [DOI:10.1016/0014-5793(87)80078-9]
11. Tanaka T, Isono T, Yoshiki T, Yuasa T, Okada Y. A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer research. 2000; 60(1): 56-9.
12. Mitchell H Sokoloff, William B Isaacs, Leland WK Chung. prostate cancer. Chapter 10. 2006.
13. Loeb S, Catalona WJ. What to do with an abnormal PSA test. The Oncologist. 2008;13(3): 299-305. [DOI:10.1634/theoncologist.2007-0139]
14. Yu H, Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc. 1999; 151(4): 209-13.
15. Abrahamsson PA, Lilja H, Falkmer S, Wadströ L. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. The Prostate. 1988; 12(1): 39-46. [DOI:10.1002/pros.2990120106]
16. Hakalahti L, Vihko P, Henttu P, Vihko R, Autio‐Harmainen H, Soini Y. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern‐blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. International journal of cancer. 1993; 55(4): 590-7. [DOI:10.1002/ijc.2910550413]
17. Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. The Journal of urology. 2002;168(2): 599-604. [DOI:10.1016/S0022-5347(05)64687-3]
18. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European urology. 2001; 39(2): 151-8. [DOI:10.1159/000052430]
19. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level≤ 4.0 ng per milliliter. New England Journal of Medicine. 2004; 350(22): 2239-46. [DOI:10.1056/NEJMoa031918]
20. Reed AB, Parekh DJ. Biomarkers for prostate cancer detection. Expert review of anticancer therapy. 2010; 10(1): 103-14. [DOI:10.1586/era.09.168]
21. Levesque M, Hu H, Diamandis EP, D'Costa M. Prostate‐Specific antigen expression by various tumors. J Clin Lab Anal. 1995; 9(2): 123-8. [DOI:10.1002/jcla.1860090209]
22. Ogawa O, Iinuma M, Sato K, Sasaki R, Shimoda N, Satoh S, et al. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy. Urological research. 1999; 27(4): 291-6. [DOI:10.1007/s002400050126]
23. Zhang L, Wang C-Y, Yang R, Shi J, Fu R, Chen L, et al. editors. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol. 2008; 26 [DOI:10.1016/j.urolonc.2007.07.016]
24. Ylikoski A, Pettersson K, Nurmi J, Irjala K, Karp M, Lilja H, et al. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease. Clinical Chemistry. 2002; 48(8): 1265-71.
25. Straub B, Müller M, Krause H, Schrader M, Miller K. Quantitative real-time RT-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients. Oncology. 2003;65(Suppl. 1):12-7. [DOI:10.1159/000072486]
26. Lintula S, Vesalainen S, Rannikko A, Zhang W-M, Finne P, Stenman J, et al. Quantification of prostate specific antigen mRNA levels in circulation after prostatic surgery and endocrine treatment by quantitative reverse transcription-polymerase chain reaction. Scandinavian journal of clinical & laboratory investigation. 2004; 64(2): 93-100. [DOI:10.1080/00365510410004191]
27. Zambon C-F, Basso D, Prayer-Galetti T, Navaglia F, Fasolo M, Fogar P, et al. Quantitative PSA mRNA determination in blood: A biochemical tool for scoring localized prostate cancer. Clinical biochemistry. 2006; 39(4): 333-8. [DOI:10.1016/j.clinbiochem.2006.02.001]
28. Meola J, Goulart LR, Oliveira JD, Neves AF, Oliveira Jr WP, Saraiva AC, et al. Differential expression of the KLK2 and KLK3 genes in peripheral blood and tissues of patients with prostate cancer. Genetics and Molecular Biology. 2006; 29(2): 193-9. [DOI:10.1590/S1415-47572006000200001]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2007 All Rights Reserved | Medical Laboratory Journal